2025 | 2024 | |
|---|---|---|
Included in profit/(loss) for the year are: | ||
Decrease in inventories of finished goods and work in progress | (75) | (1,774) |
(Decrease)/increase in raw materials and consumables used | (2,004) | 1,897 |
Inventory write-down | 575 | 2,102 |
Employee benefits expenses | 40,125 | 36,245 |
Operating lease charges (note 12) | 176 | 221 |
Amortisation of intangible fixed assets and right-of-use-assets (notes 12 and 13) | 1,111 | 1,064 |
Depreciation of PPE and right-of-use assets (notes 11 and 12) | 7,575 | 7,919 |
Impairment of PPE | 204 | 2,101 |
Disposal of assets | 20 | 28 |
Research and development costs qualified for tax relief | 1,584 | 1,400 |
Development costs capitalised (note 13) | – | (2,859) |
Net exchange losses/(gains) | 440 | (754) |
Exceptional costs* | 946 | 15,178 |
External Auditor’s remuneration: | ||
Group: fees payable to the Group’s External Auditor for the audit of the Company and consolidated financial statements: | ||
PKF Littlejohn LLP | 291 | 245 |
Fees payable to the External Auditor in respect of other services: | ||
Audit-related assurance services PKF Littlejohn LLP | 39 | 15 |
Total cost of sales, distribution costs and administrative expenses | 135,919 | 129,661 |
* Exceptional costs relate to the one-off closure costs of the MuCell business at the end of 2024. Additional costs were incurred in 2025 relating to the ongoing costs of licensing the IP of ReZorce for the next two years that were not foreseen at the end of 2024.